Coagulopathy

Advancements in Hemophilia Treatment Propel Global Bleeding Disorders Market to New Heights by 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 2, 2023
General Health, Health, Cardiology, Online, Antifibrinolytic, Pharmacy technician, Bleeding, Pharmacotherapy, S.A, Bayer, Takeda Pharmaceutical Company, Haemophilia, Market, Octapharma, Pfizer, Novo Nordisk, Coagulopathy, Government, Hospital, CSL Limited, Von Willebrand disease, Patient, Developed country, Pharmacy, Blood, Distribution, Sanofi, Growth, Haemophilia A, Pharmaceutical industry, Dentistry, Birth control, Health care

This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.

Key Points: 
  • This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.
  • Bleeding disorders encompass a group of conditions characterized by abnormal bleeding due to deficiencies or dysfunction in certain clotting factors in the blood.
  • Several factors are contributing to the growth of the bleeding disorders market, including:
    Rapid advancements in bleeding disorder treatment.
  • North America holds a major share of the bleeding disorders market, while Asia-Pacific is expected to witness the highest CAGR.

ImmunoTek Brings Awareness to the High Demand for Blood Plasma Donations

Retrieved on: 
Monday, October 2, 2023
Biotechnology, General Health, Other Health, Health, Medical Supplies, Freedom, Therapy, Blood, Quality of life, JBL, Coagulopathy, Plasma, Patient, Immunodeficiency, PID, Plasmapheresis, Rare, Parnell, Medical device, Haemophilia

Donors who visit ImmunoTek Plasma and Freedom Plasma centers will receive customary financial compensation during the Plasma Extravaganza.

Key Points: 
  • Donors who visit ImmunoTek Plasma and Freedom Plasma centers will receive customary financial compensation during the Plasma Extravaganza.
  • Plasma, the vital protein-rich component of blood, is in high demand worldwide.
  • Parnell also serves on the Global Plasma Board of Directors for the Plasma Proteins Therapeutic Association, the organization behind International Plasma Awareness Week.
  • Notably, treating just one patient for one year requires between 130 (PID) and 1200 (Hemophilia) plasma donations from healthy donors, underscoring the crucial importance of plasma donations.

Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohs Micrographic Surgery, Cancer Journal Reports

Retrieved on: 
Monday, October 2, 2023
Columbia University, Contraindication, Columbia University Irving Medical Center, Cleveland Clinic, SCC, Radiation, Probability, University, Coagulopathy, Doctor of Philosophy, Skin, Anatomy, ASTRO, Mohs surgery, SRT, Skin cancer, Cancer, NMSC, MMS, BCC, Head, National Comprehensive Cancer Network, Toxicity, Research, Radiation therapy, Neck, SCCS, Medical Subject Headings, Dermatology, Incidence, Death, Patient, Treatment, University of South Florida College of Medicine, Carcinoma, American Society for Radiation Oncology, PubMed, European Society for Medical Oncology, Recurrence, Society, Medical imaging, Veterinary medicine, Dentistry, Pharmaceutical industry, Physician, Surgeon

BURR RIDGE, Ill., Oct. 2, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT, or IGSRT), today announced a newly published study revealing that IGSRT technology is superior to Mohs micrographic surgery (MMS). Image-Guided SRT is the most advanced nonsurgical treatment for common skin cancers. This peer-reviewed study "supports IGSRT as an effective treatment option for individuals with early stage NMSCs (nonmelanoma skin cancers)." The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.

Key Points: 
  • The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.
  • The report, entitled, "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery," appears in the journal Clinical and Translational Radiation Oncology , which is published by the European Society for Radiotherapy & Oncology (ESTRO).
  • Medical Subject Headings were used to search PubMed for reports of 2-year recurrence probability rates of NMSCs treated by MMS.
  • The authors observe that prior to the invention of Mohs surgery, superficial radiation therapy (SRT) was a standard therapy offered by dermatologists for nonmelanoma skin cancer.

Pathway to Cures Announces First Venture Investment

Retrieved on: 
Tuesday, September 5, 2023
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Genetics, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, Database, Therapy, Haemophilia, Scientific Advisory Group, Coagulopathy, RNA, Transcriptome, Metabolic syndrome, Patient, Algorithm, Blood, Anemia, Sickle cell disease, Biology, Knowledge, Disease, Pharmaceutical industry, Vaccine

Pathway to Cures (P2C) announced today its inaugural investment of $250,000 in Anvesana to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its inaugural investment of $250,000 in Anvesana to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “Anvesana is delighted to be working with Pathway to Cures to develop therapeutics that will bring life altering cures to individuals suffering from the devastating effects of inheritable blood and bleeding disorders,” said Eric Ekland, PhD., CEO of Anvesana.
  • “Being able to support Anvesana in its early-stage research is an incredible step in launching our investment strategy to attract the best science and technology to the inheritable blood and bleeding disorder space,” said Teri Willey, Managing Director for Pathway to Cures.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

FDA's greenlighting of maternal RSV vaccine represents a major step forward in protecting young babies against the virus

Retrieved on: 
Monday, August 28, 2023
Insurance, Cold medicine, Bronchiolitis, DPT vaccine, Pregnancy, Placenta, Urinary tract infection, Life, Vaccination, Hospital, Clinical trial, Parent, Infection, Diphtheria, Coagulopathy, History, Antibody, Respiratory syncytial virus, Mother, CDC, Pain, Death, RSV, Swelling, Risk, Child, Immunodeficiency, Korea Disease Control and Prevention Agency, Frustration, Preterm birth, Tetanus, Infant, Center, Birth, FDA, Pneumonia, Food, Safety, Vaccine, Birth control, Nirsevimab

RSV is the most common cause of lower respiratory infections in young children and can be especially severe for infants under 6 months of age.

Key Points: 
  • RSV is the most common cause of lower respiratory infections in young children and can be especially severe for infants under 6 months of age.
  • It is the leading cause of infant hospitalization in the U.S., according to the Centers for Disease Control and Prevention.
  • Each year, RSV is associated with half a million emergency room visits, nearly 100,000 hospitalizations and 300 deaths in young U.S. children.
  • The approval of a maternal vaccine and monoclonal antibody signals a major milestone in the medical profession’s ability to prevent RSV disease in children.

A game-changer in the fight against RSV

    • Abrysvo stimulates the mother’s immune system to produce antibodies that cross the placenta and offer protection to the newborn against RSV illness, starting at birth.
    • In the trial, the maternal RSV vaccine prevented 82% of severe lower-respiratory illnesses caused by RSV in infants in the first 3 months of life, and 69.4% through 6 months of age.
    • Abrysvo was also approved by the FDA in May 2023 to prevent RSV illness in adults 60 years and older.

Monoclonal antibodies also provide protection

    • For those who are unable to get the RSV vaccine during their pregnancy, there is also an option to provide ready-made antibodies to protect the baby.
    • These antibodies help protect against lower-respiratory tract disease, including bronchiolitis and pneumonia, caused by RSV.

Parsing the differences

    • Clinical trials showed that the vaccine was protective up to 6 months of age and the antibody up to 5 months of age.
    • While Abrysvo stimulates the production of the mother’s own antibodies that get passed on to the baby, Beyfortus is not actually a vaccine.
    • It instead provides ready-made antibodies given as an injection to protect the child.
    • The cost of Abrysvo and how it will be covered by insurance will depend on what the CDC says in October.

The bottom line

    • Both products are safe and effective, and it is important to protect young infants and children at risk from RSV.
    • Until now, effective monoclonal antibodies were only available for the most premature babies.

ImmunoTek Plasma Opens Second Donation Center in Illinois

Retrieved on: 
Monday, August 28, 2023
Biotechnology, General Health, Health, Other Health, Quincy Center, Plasma, Cancer, Burn, Plasmapheresis, Patient, Coagulopathy, Blood, Medical device

On Tuesday, August 29, 2023, ImmunoTek Plasma will open its new state-of-the-art donation center, allowing individuals to discover the life-saving benefits of donating plasma while earning extra income.

Key Points: 
  • On Tuesday, August 29, 2023, ImmunoTek Plasma will open its new state-of-the-art donation center, allowing individuals to discover the life-saving benefits of donating plasma while earning extra income.
  • The United States provides 2/3 of the world's plasma, and its need increases between 6% - 8% yearly.
  • "In addition to donor compensation, the new ImmunoTek donation center will create new jobs in Quincy, and we anticipate making a $5 million economic impact yearly."
  • "ImmunoTek Plasma eagerly anticipates bolstering the local economy by creating job opportunities and fostering growth as a dedicated participant in the local community.

The National Hemophilia Foundation is Now the National Bleeding Disorders Foundation

Retrieved on: 
Friday, August 18, 2023
Genetics, Hispanic, Philanthropy, Family, AIDS, General Health, Pharmaceutical, Consumer, Health, Foundation, National Hemophilia Foundation, National Harbor, Maryland, Education, NHF, Health equity, Haemophilia, Research, Coagulopathy, Disorder, Von Willebrand disease, Blood, Giant platelet disorder, Conference, Social media, BISU Visual Identity, Dentistry, Management, MD, Cardiology

The National Hemophilia Foundation (NHF) has officially changed its name to the National Bleeding Disorders Foundation (NBDF).

Key Points: 
  • The National Hemophilia Foundation (NHF) has officially changed its name to the National Bleeding Disorders Foundation (NBDF).
  • Foundation leaders announced the change alongside advocates and supporters at the 2023 Bleeding Disorders Conference in National Harbor, MD.
  • In addition to the new name, the National Bleeding Disorders Foundation unveiled a new visual identity and logo intended to represent a wide range of inheritable blood and bleeding disorders, as well as a new tagline: Innovate | Educate | Advocate.
  • No matter what disorder you have, you will find a home in the National Bleeding Disorders Foundation,” said Dr. Len Valentino, CEO.

ImmunoTek Bio Centers Celebrates 10th Anniversary

Retrieved on: 
Wednesday, July 26, 2023
Biotechnology, General Health, Health, Medical Supplies, Biopharmaceutical, Freedom, Shock, Coagulopathy, Plasma, Collection, Patient, Blood, Growth, Rare, FDA, Pharmaceutical industry, Medical device

This month we celebrate the 10th anniversary of ImmunoTek Bio Centers, the world's largest and fastest-growing independent blood plasma collection company.

Key Points: 
  • This month we celebrate the 10th anniversary of ImmunoTek Bio Centers, the world's largest and fastest-growing independent blood plasma collection company.
  • ImmunoTek launched ten years ago to build and operate plasma donation centers nationwide to help meet the growing demand for blood plasma.
  • Since its formation on July 18, 2013, the company has accepted more than seven million paid donations at its collection centers.
  • We have an incredibly talented team and a solid operating platform that is fueling our growth for the next decade.”
    Through its two subsidiaries, ImmunoTek Plasma and Freedom Plasma, ImmunoTek Bio Centers operates 45 centers in 21 states, with over a dozen more in development.

Pathway to Cures Names First Members to Scientific Advisory Group

Retrieved on: 
Tuesday, July 18, 2023
Philanthropy, Health, Genetics, Fund Raising, Foundation, Pharmaceutical, Biotechnology, National Hemophilia Foundation, Bleeding, NHF, Gene editing, United States Air Force Scientific Advisory Board, Scientific Advisory Group, MBA, Scientific Advisory Group for Emergencies, Doctor of Philosophy, Science, Anemia, Blood, Sickle cell disease, Coagulopathy, Knowledge, Haemophilia, Pharmaceutical industry, MD, Pathway

Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group.

Key Points: 
  • Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group.
  • Leonard Valentino, MD, P2C’s Chief Executive Officer and NHF President and CEO, also serves on the Scientific Advisory Group.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Hemophilia Foundation (NHF) and chairs the Pathway to Cures Scientific Advisory Group.
  • P2C’s Scientific Advisory Board makes recommendations to the P2C Investment Committee regarding promising opportunities.